Poorly controlled asthma – Easy wins and future prospects for addressing fungal allergy

  • Denning David W.
    Manchester Fungal Infection Group, The University of Manchester and Manchester Academic Health Science Centre
  • Pfavayi Lorraine T.
    Institute of Immunology & Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh

書誌事項

タイトル別名
  • Poorly controlled asthma — Easy wins and future prospects for addressing fungal allergy

抄録

<p>Poorly controlled asthma is especially common in low resource countries. Aside from lack of access to, or poor technique with, inhaled beta-2 agonists and corticosteroids, the most problematic forms of asthma are frequently associated with both fungal allergy and exposure, especially in adults leading to more asthma exacerbations and worse asthma. The umbrella term ‘fungal asthma’ describes many disorders linked to fungal exposure and/or allergy to fungi. One fungal asthma endotype, ABPA, is usually marked by a very high IgE and its differential diagnosis is reviewed. Both ABPA and fungal bronchitis in bronchiectasis are marked by thick excess airway mucus production. Dermatophyte skin infection can worsen asthma and eradication of the skin infection improves asthma. Exposure to fungi in the workplace, home and schools, often in damp or water-damaged buildings worsens asthma, and remediation improves symptom control and reduces exacerbations. Antifungal therapy is beneficial for fungal asthma as demonstrated in nine of 13 randomised controlled studies, reducing symptoms, corticosteroid need and exacerbations while improving lung function. Other useful therapies include azithromycin and some biologics approved for the treatment of severe asthma. If all individuals with poorly controlled and severe asthma could be ‘relieved’ of their fungal allergy and infection through antifungal therapy without systemic corticosteroids, the health benefits would be enormous and relatively inexpensive, improving the long term health of over 20 million adults and many children. Antifungal therapy carries some toxicity, drug interactions and triazole resistance risks, and data are incomplete. Here we summarise what is known and what remains uncertain about this complex topic.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (202)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ